Clinical Practice Liaison- New York at Acadia Pharmaceuticals

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceuticals, HealthcareIndustries

Requirements

Advanced healthcare or life science degree (e.g., PA, NP, PharmD, or other clinically relevant background)
Minimum 5 years of direct patient care in gastroenterology, hepatology, endocrinology, or metabolic disease
Clinical familiarity with NASH/MASH diagnostic tools, especially non-invasive testing and risk stratification methods
Strong grasp of U.S. healthcare system operations, including practice workflows, billing/coding, and payer dynamics
Excellent verbal and written communication skills; ability to distill complex science for various audiences
Proficiency with Microsoft Office tools, CRM platforms, and virtual communication systems
Willingness to travel 60–70% weekly, including weekends for scientific congresses

Responsibilities

Deliver unbiased, evidence-based education on MASH/NASH to HCPs based on identified gaps in knowledge or clinical implementation
Present current clinical practice guidelines and real-world data on diagnosis, risk stratification, and patient management
Maintain deep understanding of non-invasive testing (NITs), treatment paradigms, and clinical protocols across the liver/metabolic spectrum
Engage with clinicians, practice managers, and office staff to support implementation of MASH care protocols
Support the integration of guideline-based approaches into routine clinical workflows and align practices with payer and quality standards
Respond to unsolicited clinical and drug-related inquiries in a scientifically accurate and compliant manner
Partner with internal Medical Affairs and Commercial colleagues to address clinical questions and ensure consistent field insights
Contribute scientific expertise to speaker training programs, advisory boards, and internal stakeholder education
Represent Madrigal at national and regional scientific meetings, supporting booth activities and engaging in peer-to-peer exchange
Capture and report actionable insights from clinical practices to inform corporate strategies and educational content development
Monitor evolving clinical trends and barriers to care in MASH/NASH to support internal planning and market awareness
Adhere strictly to all applicable company and regulatory policies, including FDA and industry guidelines for non-promotional medical engagements
Ensure thorough documentation and accountability for all scientific interactions

Skills

MASH

NASH

Clinical Education

HCP Engagement

Evidence-Based Education

Non-Invasive Testing

Risk Stratification

Medical Affairs

Endocrinology

Hepatology

Disease Management

Clinical Guidelines

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free